OTCMKTS:ARTH Arch Therapeutics (ARTH) Stock Price, News & Analysis $0.77 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.68▼$0.9050-Day Range$0.62▼$1.4952-Week Range$0.39▼$18.00Volume50 shsAverage Volume4,575 shsMarket Capitalization$3.64 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsSEC FilingsShort Interest Get Arch Therapeutics alerts: Email Address Ad DTIHow a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…Click now to see for yourself what $0.25 Cent Trades is all about About Arch Therapeutics Stock (OTCMKTS:ARTH)Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.Read More ARTH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARTH Stock News HeadlinesJuly 16, 2024 | americanbankingnews.comArch Therapeutics, Inc. (OTCMKTS:ARTH) Short Interest UpdateMay 6, 2024 | globenewswire.comArch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Spring Meeting (SAWC Spring)July 26, 2024 | WealthPress (Ad)This TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.February 8, 2024 | msn.comArch Therapeutics Secures $750K Prepayment for StockJanuary 6, 2024 | morningstar.comArch Therapeutics Inc ARTHNovember 23, 2023 | msn.comAre Medical Stocks Lagging Arch Therapeutics (ARTH) This Year?November 9, 2023 | finanznachrichten.deArch Therapeutics, Inc.: Arch Therapeutics Provides Year End Operational UpdateNovember 9, 2023 | finance.yahoo.comArch Therapeutics Provides Year End Operational UpdateJuly 26, 2024 | WealthPress (Ad)This TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.November 2, 2023 | finance.yahoo.comArch Therapeutics to Present AC5® Advanced Wound System at the 2023 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall)September 13, 2023 | finance.yahoo.comArch Therapeutics Provides AC5® Commercialization UpdateSeptember 8, 2023 | finanznachrichten.deArch Therapeutics, Inc.: Arch Therapeutics Completes Financing as Bridge to UplistingSeptember 7, 2023 | finance.yahoo.comArch Therapeutics Completes Financing as Bridge to UplistingJuly 8, 2023 | health.usnews.comDr. Arth PatelJune 13, 2023 | travel.usnews.comDouble ArchApril 25, 2023 | finance.yahoo.comArch Therapeutics to Present AC5® Advanced Wound System at 2023 Symposium on Advanced Wound Care (“SAWC”)April 5, 2023 | finance.yahoo.comDedicated HCPCS Billing Code for Arch Therapeutics’ AC5® Advanced Wound System Now In EffectMarch 20, 2023 | investing.comArch Therapeutics Inc (ARTHD)See More Headlines Receive ARTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arch Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolOTCMKTS:ARTH Previous SymbolNASDAQ:ARTH CUSIPN/A CIK1537561 Webwww.archtherapeutics.com Phone(617) 431-2313FaxN/AEmployees8Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,980,000.00 Net Margins-6,460.51% Pretax Margin-6,460.51% Return on EquityN/A Return on Assets-489.95% Debt Debt-to-Equity RatioN/A Current Ratio0.12 Quick Ratio0.02 Sales & Book Value Annual Sales$80,000.00 Price / Sales45.50 Cash FlowN/A Price / Cash FlowN/A Book Value($2.43) per share Price / Book-0.32Miscellaneous Outstanding Shares4,740,000Free Float4,529,000Market Cap$3.64 million OptionableNot Optionable Beta3.59 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Terrence W. Norchi M.D. (Age 59)Co-Founder, Chairman, President & CEO Comp: $450.5kMr. Michael S. Abrams (Age 54)CFO & Treasurer Comp: $325kDr. Rutledge Ellis-Behnke Ph.D.Co-Founder & Scientific AdvisorMr. Shawn CarlsonVice President of SalesKey CompetitorsInspira Technologies Oxy B.H.N.NASDAQ:IINNVapothermNYSE:VAPOPetVivoNASDAQ:PETVSTRATA Skin SciencesNASDAQ:SSKNPAVmedNASDAQ:PAVMView All Competitors ARTH Stock Analysis - Frequently Asked Questions How have ARTH shares performed this year? Arch Therapeutics' stock was trading at $7.24 at the start of the year. Since then, ARTH shares have decreased by 89.4% and is now trading at $0.7680. View the best growth stocks for 2024 here. How were Arch Therapeutics' earnings last quarter? Arch Therapeutics, Inc. (OTCMKTS:ARTH) announced its quarterly earnings data on Thursday, May, 9th. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter. The biotechnology company had revenue of $0.03 million for the quarter. How do I buy shares of Arch Therapeutics? Shares of ARTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Arch Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arch Therapeutics investors own include Anavex Life Sciences (AVXL), POET Technologies (POETF), Aptose Biosciences (APTO), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX) and Bellerophon Therapeutics (BLPH). This page (OTCMKTS:ARTH) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arch Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arch Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARTH Stock Alerts